Plain-English translation of NCT07306286 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for locally advanced pancreatic cancer in people whose cancer has stopped responding to standard first-line chemotherapy. The treatment combines cryoablation—a procedure that freezes and destroys cancer tissue—with Apalulizumab, a medication that helps your immune system recognize and fight cancer cells. The study aims to see if this two-pronged approach is safe and effective as a second-line treatment option.
Pancreatic cancer is very challenging to treat, and many patients' cancers stop responding to standard chemotherapy. Researchers want to explore whether combining a freezing procedure with this medication might give patients whose cancer has progressed a new treatment option with better outcomes.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the cryoablation procedure to freeze your pancreatic tumor, followed by doses of the immune-boosting medication. The study involves 20 participants total, and you would attend clinic visits for treatment administration, safety monitoring, and imaging scans to see how your cancer responds. The exact schedule and duration of treatment would be determined by your medical team based on how well the treatment works and how you tolerate it.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China